Late last year Regado Biosciences came up with a big $51 million round that served as a kind of down payment on a planned $120 million study of its lead therapy--an anticoagulant that adds a promising "real-time" therapeutic tool to dial the effect up and down in order to control bleeding risks. Not willing to take any offers on the table, though, Regado still had to come up with the rest of the money. And now it's sprung a $75 million IPO designed to take it all the way through Phase III.
What would top Xarelto for Bayer and Johnson & Johnson? Xarelto with an easy antidote.
The big news in generic drugs in the last couple of years has been all of the marquee brands that are getting their tails kicked by generic competition . The best example is the loss of the patent on...
The case of a Pradaxa user who died after a minor fall is raising more questions about the drug's safety.
Just days after Pfizer ( $PFE ) and Bristol-Myers Squibb ( $BMY ) offered up stellar safety and efficacy data on their anti-clotting therapy Eliquis, researchers revealed that Astellas's oral